What We’re Reading: Priority Review for Merck Pneumococcal Vaccine; Bluebird Bio Splits Into 2 Companies; Novel Coronavirus Variant in Japan
FDA accepts for priority review a Biologics License Application for V114, Merck's investigational 15-valent pneumococcal conjugate vaccine; bluebird bio will be split into 2 publicly traded drug companies; a new variant of coronavirus is reported in Japan.
FDA Accepts BLA for Merck’s Pneumococcal Conjugate Vaccine
Today, Merck
Biotech Company Bluebird Will Split Into 2 Companies
According to the
Novel Coronavirus Variant Found in Japan
Yesterday, the World Health Organization (WHO) said that a new variant of the novel coronavirus was reported in Japan and found in 4 people arriving from Brazil, although details of whether the variant is more infectious, like that found in the
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025